Key HIV Studies Influencing My Practice Following 2018 Fall Conferences

IDWeek 2018; October 3-7, 2018; San Francisco, California
20th International Workshop on Co-morbidities and Adverse Drug Reactions in HIV; October 13-14, 2018; New York, New York
HIV Drug Therapy Glasgow 2018; October 28-31, 2018; Glasgow, United Kingdom
Listen to downloadable audio from a live Webinar in which CCO’s expert faculty assessed how new HIV data reported at fall 2018 conferences will affect clinical practice and answered questions from participants.
David A. Wohl, MD
Format: .mp3
File Size: 6.22 MB
Released: November 12, 2018

Acknowledgements

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ACHS Logo

Contact Clinical Care Options

For customer support please email: customersupport@clinicaloptions.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Educational grants provided by
Gilead Sciences
Janssen Therapeutics
ViiV Healthcare

Related Content

Interim results from the Phase II CALIBRATE study of lenacapavir in treatment-naive PLWH, reported by Clinical Care Options (CCO) from IAS 2021

Released: July 24, 2021

REACH study: adherence to dapivirine vaginal ring and oral PrEP among African females 16-21 years, in Clinical Care Options (CCO) report from IAS 2021

Released: July 24, 2021

GEMS: ART resistance, adherence in persons with HIV on PrEP in Sub-Saharan Africa, reported by Clinical Care Options (CCO) from IAS 2021

Released: July 24, 2021

Dr Joseph Eron and Clinical Care Options (CCO): Weight gain in initial ART, GEMINI, ADVANCE trials, and more

Joseph J. Eron, Jr., MD Released: July 22, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue